LoginSignup
CEL-SCI logo

CEL-SCI

Stock
Stock
ISIN: US1508376076
Ticker: CVM
US1508376076
CVM

Price

Price

CHART BY

Historical dividends and forecast

All dividend data

 

$62.50

CHART BY

Frequently asked questions

What is CEL-SCI's market capitalization?

The market capitalization of CEL-SCI is $29.18M. Market capitalization is a measure of the total market value of a publicly traded company. It is calculated by multiplying the current stock price by the total number of outstanding shares.

What is the Earnings Per Share (EPS) for CEL-SCI?

CEL-SCI's Earnings Per Share (EPS) over the trailing twelve months (TTM) is -$0.501. EPS indicates the company's profitability on a per-share basis.

What are the analyst ratings and target price for CEL-SCI's stock?

Currently, 1 analysts cover CEL-SCI's stock, with a consensus target price of $6.20. Analyst ratings provide insights into the stock's expected performance.

What is the EBITDA for CEL-SCI?

CEL-SCI's Earnings before interest, taxes, depreciation, and amortization (EBITDA) over the trailing twelve months is -$22.38M. EBITDA measures the company's overall financial performance.

What is the free cash flow of CEL-SCI?

CEL-SCI has a free cash flow of -$18.91M. Free cash flow indicates the cash generated after accounting for cash outflows to support operations and capital assets.

What is the free float of CEL-SCI's shares?

The free float of CEL-SCI is 72.06M. Free float refers to the number of shares available for public trading, excluding restricted shares.

Financials

Market Cap 
$29.18M
EPS (TTM) 
-$0.501
Free Float 
72.06M
EBITDA (TTM) 
-$22.38M
Free Cashflow (TTM) 
-$18.91M

Pricing

1D span
$0.39$0.409
52W span
$0.357$3.08

Analyst Ratings

The price target is $6.20 and the stock is covered by 1 analysts.

Buy

1

Hold

0

Sell

0

Information

CEL-SCI Corp. is a clinical-stage biotechnology company, which engages in the research, development, and manufacture of investigational immunotherapy products for the treatment of cancer and infectious diseases. Its product pipeline includes Multikine and Ligand Epitope Presentation System (LEAPS). Multikine is an investigational immunotherapy for the potential treatment of head and neck cancers. LEAPS is categorized into LEAPS-H1N1-DC, a product candidate for the treatment of pandemic influenza for hospitalized patients and CEL-2000 and CEL-4000, which are vaccine candidates for the treatment of rheumatoid arthritis. The company was founded by Maximilian de Clara on March 22, 1983 and is headquartered in Vienna, VA.

Industries
Biotechnology
Sector
Health Care

Identifier

ISIN
US1508376076
Primary Ticker
CVM

Knockouts

Join the conversation
Sign upLogin